CD38 and Miyoshi myopathy: The integration of novel drugs into the treatment landscape of MM, including proteasome inhibitors, immunomodulatory drugs, and CD38-targeting antibodies, as well as, more recently CAR-T-cell therapy in later treatment lines, has resulted in a sustained increase in life expectancy in patients with MM [1].